Once-a-day Immunosuppression(CISECON_a_day)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

Also called NCT01964014

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 160 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01964014
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01964014. Allocation not applicable; no masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Once-a-day Immunosuppression(CISECON_a_day)
Acronym
CISECON
Condition
Chronic Renal Disease
Intervention (Drug)
advagrf
Lead sponsor
Ajou University School of Medicine (class: other)

Record details

Record id
cardio:ct-nct01964014
Content hash
e2da817e28f7479a411b3594474a43a9aa8092639a15965aaa72641c6dbea76d